Table 6.
|
Telavancin |
Standard therapy |
---|---|---|
n/N | n/N | |
Hematocrit |
|
|
Male, ≤30% |
1/4 (25%) |
0/1 (0%) |
Female, ≤28% |
0/4 (0%) |
0/3 (0%) |
WBC ≤2800/μl |
0/14 (0%) |
0/15 (0%) |
Platelet count ≤75,000/μl |
0/18 (0%) |
0/13 (0%) |
AST (≥3 ULN) |
3/18 (17%) |
0/18 (0%) |
ALT (≥3 ULN) |
1/19 (5%) |
1/17 (6%) |
Alkaline phosphatase (≥1.5 ULN) |
2/17 (12%) |
1/22 (5%) |
Potassium <3 meq/l |
2/24 (8%) |
0/19 (0%) |
Potassium >5.5 meq/l |
1/24 (4%) |
3/19 (16%) |
Creatinine increase
b
|
5/25 (20%) |
2/28 (7%) |
Baseline creatinine <1.5 mg/dl |
4/18 (22%) |
0/20 (0%) |
Baseline creatinine ≥1.5 mg/dl | 1/7 (14%) | 2/8 (25%) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase, ULN, upper limit of normal; WBC, white blood count.
a Includes laboratory assessments after initiation of study drug up to and including the earlier of the follow-up visit or 28 days after the last dose of study medication.
b Serum creatinine ≥1.5 mg/dl and at least 50% greater than baseline; includes patients with normal and abnormal values at baseline.